A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity.
Sign Up to like & getrecommendations! Published in 2019 at "Tuberculosis"
DOI: 10.1016/j.tube.2019.06.005
Abstract: Bedaquiline was approved by USFDA in 2012 for pulmonary MDR-TB. The IC50 value of bedaquiline was reported to be remarkably low (25 nM), effectively inhibiting mycobacterial ATP synthase. In addition to these obvious assets of bedaquiline,… read more here.
Keywords: insight bedaquiline; structural insight; cardiotoxicity hepatotoxicity; bedaquiline ... See more keywords